RU2757221C2 - Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение - Google Patents

Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение Download PDF

Info

Publication number
RU2757221C2
RU2757221C2 RU2016135930A RU2016135930A RU2757221C2 RU 2757221 C2 RU2757221 C2 RU 2757221C2 RU 2016135930 A RU2016135930 A RU 2016135930A RU 2016135930 A RU2016135930 A RU 2016135930A RU 2757221 C2 RU2757221 C2 RU 2757221C2
Authority
RU
Russia
Prior art keywords
antipsychotic drug
pyrido
dimethoxy
hexahydro
isobutyl
Prior art date
Application number
RU2016135930A
Other languages
English (en)
Russian (ru)
Other versions
RU2016135930A3 (enExample
RU2016135930A (ru
Inventor
Сэмюэл Роджер Джесс ХОАР
Original Assignee
Ньюрокрайн Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрокрайн Байосайенсиз, Инк. filed Critical Ньюрокрайн Байосайенсиз, Инк.
Publication of RU2016135930A publication Critical patent/RU2016135930A/ru
Publication of RU2016135930A3 publication Critical patent/RU2016135930A3/ru
Application granted granted Critical
Publication of RU2757221C2 publication Critical patent/RU2757221C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016135930A 2014-02-07 2015-02-06 Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение RU2757221C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937223P 2014-02-07 2014-02-07
US61/937,223 2014-02-07
PCT/US2015/014893 WO2015120317A1 (en) 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021128797A Division RU2021128797A (ru) 2014-02-07 2015-02-06 Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Publications (3)

Publication Number Publication Date
RU2016135930A RU2016135930A (ru) 2018-03-15
RU2016135930A3 RU2016135930A3 (enExample) 2018-10-05
RU2757221C2 true RU2757221C2 (ru) 2021-10-12

Family

ID=52589782

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016135930A RU2757221C2 (ru) 2014-02-07 2015-02-06 Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
RU2021128797A RU2021128797A (ru) 2014-02-07 2015-02-06 Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021128797A RU2021128797A (ru) 2014-02-07 2015-02-06 Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Country Status (12)

Country Link
US (4) US9782398B2 (enExample)
EP (2) EP3102239A1 (enExample)
JP (4) JP6718376B2 (enExample)
KR (1) KR102328058B1 (enExample)
CN (3) CN106061506A (enExample)
AU (1) AU2015213778B2 (enExample)
CA (1) CA2938581C (enExample)
IL (1) IL247127B (enExample)
MX (1) MX378664B (enExample)
NZ (2) NZ723107A (enExample)
RU (2) RU2757221C2 (enExample)
WO (1) WO2015120317A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140647A (ko) * 2014-05-06 2022-10-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
MX375718B (es) 2015-02-06 2025-03-06 Neurocrine Biosciences Inc [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EP3473623B1 (en) 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
KR102506333B1 (ko) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
EP3789029B1 (en) * 2018-05-04 2024-05-08 Korea Institute of Radiological & Medical Sciences Radiation sensitivity enhancing composition containing aripiprazole as active ingredient
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020188551A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for treating autism spectrum disorder and associated disorders
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2024524324A (ja) * 2021-06-30 2024-07-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症のアドオン処置において使用するためのバルベナジン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011897A1 (en) * 1996-09-23 1998-03-26 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them
US20080167337A1 (en) * 2006-11-08 2008-07-10 Gano Kyle W Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US20110257220A1 (en) * 2005-08-06 2011-10-20 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011897A1 (en) * 1996-09-23 1998-03-26 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them
US20080167337A1 (en) * 2006-11-08 2008-07-10 Gano Kyle W Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gary Remington, et al. Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia A 12-Week, Double-Blind, Placebo-Controlled Trial // Journal of Clinical Psychopharmacology.- 2012. -V. 32. - N. 1. - P. 95-99. *
KIMIAGAR I. et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study //Journal of neurology. - 2012. - V. 259. - N. 4. - P. 660-664. *
Wei Zhang, M.D et al. Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex // NEUROPSYCHOPHARMACOLOGY. - 2000. -V. 23. - N. 3. - P. 250-262. *
ГУЛИЕВА С.Т. и др. НЕЙРОФАРМАКОЛОГИЧЕСКИЙ АНАЛИЗ эффектов оланзапина и клозапина на поведенческие характеристики и содержание нейромедиаторов в структурах мозга крыс // Психофармакология и биологическая наркология. -2004. - N1. - С. 585- 589. *
ГУЛИЕВА С.Т. и др. НЕЙРОФАРМАКОЛОГИЧЕСКИЙ АНАЛИЗ эффектов оланзапина и клозапина на поведенческие характеристики и содержание нейромедиаторов в структурах мозга крыс // Психофармакология и биологическая наркология. -2004. - N1. - С. 585- 589. Gary Remington, et al. Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia A 12-Week, Double-Blind, Placebo-Controlled Trial // Journal of Clinical Psychopharmacology.- 2012. -V. 32. - N. 1. - P. 95-99. *

Also Published As

Publication number Publication date
MX378664B (es) 2025-03-10
CN106061506A (zh) 2016-10-26
AU2015213778A1 (en) 2016-08-18
IL247127B (en) 2021-04-29
US20190381029A1 (en) 2019-12-19
EP3102239A1 (en) 2016-12-14
US9782398B2 (en) 2017-10-10
JP2017505316A (ja) 2017-02-16
US20180085364A1 (en) 2018-03-29
CA2938581C (en) 2023-02-28
RU2016135930A3 (enExample) 2018-10-05
EP4049681A1 (en) 2022-08-31
JP2021080294A (ja) 2021-05-27
RU2021128797A (ru) 2021-11-26
CN113413385A (zh) 2021-09-21
KR20160132830A (ko) 2016-11-21
NZ723107A (en) 2022-11-25
AU2015213778B2 (en) 2020-04-23
KR102328058B1 (ko) 2021-11-17
IL247127A0 (en) 2016-09-29
CA2938581A1 (en) 2015-08-13
CN113368110A (zh) 2021-09-10
US20160339011A1 (en) 2016-11-24
US20200206215A1 (en) 2020-07-02
MX2016010071A (es) 2017-04-27
JP2019116515A (ja) 2019-07-18
JP6718376B2 (ja) 2020-07-08
RU2016135930A (ru) 2018-03-15
NZ760790A (en) 2022-11-25
WO2015120317A1 (en) 2015-08-13
JP2024003253A (ja) 2024-01-11

Similar Documents

Publication Publication Date Title
RU2757221C2 (ru) Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
US20190015396A1 (en) Vmat2 inhibitors for treating neurological diseases or disorders
US20240350453A1 (en) Methods of treating neurological and psychiatric disorders
US20240366559A1 (en) Methods of treating neurological and psychiatric disorders
JP7757036B2 (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
KR20250029267A (ko) 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
JP2011513200A (ja) 認知機能障害を治療するためのキット、組成物、製品もしくは医薬
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
HK40079434A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
HK40062589A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
HK40057761A (en) Methods of treating neurological and psychiatric disorders